Press Releases

To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.

Non Regulatory

Initiator Pharma to fully prioritize pudafensine

Initiator Pharma A/S, a clinical-stage biotech company, today announced that the company has decided to focus fully on its most promising drug candidate, pudafensine, which is being developed for both vulvodynia and organic erectile dysfunction (ED). As part of this prioritization, the company will discontinue further development of IP2018.

Read more
Non Regulatory

Initiator Pharma fokuserar helt på pudafensine

Initiator Pharma A/S, ett bioteknikbolag i klinisk fas, meddelar idag att bolaget beslutat att fokusera fullt ut på sin mest lovande läkemedelskandidat pudafensine, som utvecklas för både vulvodyni och organisk erektil dysfunktion (ED). Som en del av denna prioritering kommer bolaget att avbryta den fortsatta utvecklingen av IP2018.

Read more
Non Regulatory

Initiator Pharma erhåller europeiskt patent för pudafensine vid kvinnlig sexuell dysfunktion, inklusive vulvodyni

Initiator Pharma A/S, ett emerging pharma bolag i klinisk fas som utvecklar innovativa läkemedel som riktar sig mot viktiga ouppfyllda medicinska behov inom centrala och perifera nervsystemet, meddelade idag att Europeiska patentverket (EPO) har beviljat bolagets europeiska patentansökan avseende pudafensine för behandling av kvinnlig sexuell dysfunktion (FSD).

Read more
Non Regulatory

Initiator Pharma granted European patent for pudafensine in Female Sexual Dysfunction, including vulvodynia

Initiator Pharma A/S, a clinical-stage biotech company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, today announced that the European Patent Office (EPO) has granted the company’s European patent application covering pudafensine for the treatment of Female Sexual Dysfunction (FSD).

Read more